MRI-based Delta-radiomics Are Predictive of Pathological Complete Response After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
Overview
Authors
Affiliations
Rationale And Objectives: To investigate the capability of delta-radiomics to predict pathological complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT) in patients with locally advanced rectal cancer (LARC).
Materials And Methods: This retrospective study enrolled 165 consecutive patients with LARC (training set, n = 116; test set, n = 49) who received nCRT before surgery. All patients underwent pre- and post-nCRT MRI examination from which radiomics features were extracted. A delta-radiomics feature was defined as the percentage change in a radiomics feature from pre- to post-nCRT MRI. A data reduction and feature selection process including the least absolute shrinkage and selection operator algorithm was performed for building T2-weighted imaging (T2WI) and diffusion-weighted imaging (DWI) delta-radiomics signature. Logistic regression was used to build a T2WI and DWI combined radiomics model. Receiver operating characteristic analysis was performed to assess diagnostic performance. Delong method was used to compare the performance of delta-radiomics model with that of magnetic resonance tumor regression grade (mrTRG).
Results: Twenty-seven of 165 patients (16.4%) achieved pCR. T2WI and DWI delta-radiomics signature, and the combined model showed good predictive performance for pCR. The combined model achieved the highest areas under the receiver operating characteristic curves of 0.91 (95% confidence interval: 0.85-0.98) and 0.91 (95% confidence interval: 0.83-0.99) in the training and test sets, respectively (significantly greater than those for mrTRG; training set, p < 0.001; test set, p = 0.04).
Conclusion: MRI-based delta-radiomics can help predict pCR after nCRT in patients with LARC with better performance than mrTRG.
Enhancing the role of MRI in rectal cancer: advances from staging to prognosis prediction.
Gong X, Ye Z, Shen Y, Song B Eur Radiol. 2025; .
PMID: 40045072 DOI: 10.1007/s00330-025-11463-x.
Chen L, Zhu W, Zhang W, Chen E, Zhou W Langenbecks Arch Surg. 2024; 409(1):218.
PMID: 39017754 PMC: 11255083. DOI: 10.1007/s00423-024-03416-7.
Ramireddy J, Sathya A, Sasidharan B, Varghese A, Sathyamurthy A, John N J Gastrointest Cancer. 2024; 55(3):1199-1211.
PMID: 38856797 DOI: 10.1007/s12029-024-01073-z.
Li W, Huang Y, Zhu T, Zhang Y, Zheng X, Zhang T Ann Surg. 2024; 281(4):645-654.
PMID: 38557792 PMC: 11888841. DOI: 10.1097/SLA.0000000000006279.
Shen H, Jin Z, Chen Q, Zhang L, You J, Zhang S Radiol Med. 2024; 129(4):598-614.
PMID: 38512622 DOI: 10.1007/s11547-024-01796-w.